Alkermes Email Format

Biotechnology Research
1,001-2,500 employees
Dublin, Ireland

Alkermes is a biopharmaceutical company that develops and commercializes medicines for complex psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders.

Find contacts at Alkermes

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@alkermes.com

Company Overview

Industry
Biotechnology Research
Founded
1987
Headquarters
Dublin, Ireland
Revenue
$1B-$2.5B
FUNDING Stage
Public
Key Executives
Richard Pops (Chairman and Chief Executive Officer), Joshua Reed (Senior Vice President, Chief Financial Officer), Blair Jackson (Executive Vice President, Chief Operating Officer)

Tech Stack

Snowflake

Analytics

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Alkermes?

Alkermes uses the first.last format, so Jane Smith would be jane.smith@alkermes.com.

What approved medicines does Alkermes currently market in the United States?

Alkermes markets four proprietary medicines in the U.S.: VIVITROL for alcohol and opioid dependence, LYBALVI and ARISTADA for schizophrenia and bipolar I disorder, and LUMRYZ, a once-nightly sodium oxybate treatment for narcolepsy that joined the portfolio following the February 2026 acquisition of Avadel Pharmaceuticals.

How far along is Alkermes in developing alixorexton as a narcolepsy treatment?

Alixorexton, formerly known as ALKS 2680, is an oral orexin 2 receptor agonist currently in Phase 3 trials through the Brilliance Studies program for narcolepsy type 1 and type 2, and in Phase 2 for idiopathic hypersomnia as of 2026.

Who leads Alkermes as CEO and what is his role within the company?

Richard Pops serves as both Chairman and Chief Executive Officer of Alkermes, guiding the company's focus on neuroscience-based medicines across addiction, serious mental illness, and sleep disorders.

Can Clay help me find and verify contact information for Alkermes employees?

Yes, Clay can enrich your prospect list with verified Alkermes employee contact details, including email addresses following the first.last@alkermes.com format, making it easier to reach the right people across the company's 2,371-person workforce.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles